Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence 3 Years After aP or Tdap Booster
NCT02382913Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of acellular pertussis vaccine and tetanus toxoid + diphtheria toxoid + acellular pertussis in pertussis (10 arms), sponsored by Novartis. Primary endpoints: Geometric Mean Concentrations of Antibodies Against Pertussis Antigens at Day 1 and Geometric Mean Ratios of Antibody Concentrations at Day 1. Started Apr 2015; status: completed.
02
Drugs
acellular pertussis vaccinetetanus toxoid + diphtheria toxoid + acellular pertussis
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT02382913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382913.